首页 > 最新文献

European Clinical Respiratory Journal最新文献

英文 中文
Added value of EUS-B-FNA to bronchoscopy and EBUS-TBNA in diagnosing and staging of lung cancer. 在肺癌诊断和分期方面,EUS-B-FNA 比支气管镜检查和 EBUS-TBNA 更有价值。
IF 1.9 Q3 Medicine Pub Date : 2024-06-09 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2024.2362995
Mohammad A Issa, Paul F Clementsen, Christian B Laursen, Ida S Christiansen, Laurence Crombag, Peter Vilmann, Uffe Bodtger

Background: Bronchoscopy and EBUS are standard procedures in lung cancer work-up but have low diagnostic yield in lesions outside the central airways and hilar/mediastinal lymph nodes. Growing evidence on introducing the EBUS endoscope into the oesophagus (EUS-B) in the same session as bronchoscopy/EBUS gives access to new anatomical areas that can be safely biopsied.

Objective: To summarize the current evidence of the added value of EUS-B-FNA to bronchoscopy and EBUS-TBNA in lung cancer work-up.

Methods: A narrative review.

Results: Few randomized trials or prospective studies are available. Prospective studies show that add-on EUS-B-FNA increases diagnostic yield when sampling abnormal mediastinal lymph nodes, para-oesophageal lung and left adrenal gland. A large retrospective series on EUS-B-FNA from retroperitoneal lymph nodes suggests high diagnostic yield without safety concerns, as do casuistic reports on EUS-B-FNA from mediastinal pleural thickening, pancreatic lesions, ascites fluid and pericardial effusions. No study has systematically assessed both diagnostic yield, safety, patient reported outcomes, adverse events and costs.

Conclusion: The diagnostic value of add-on EUS-B to standard bronchoscopy and EBUS in lung cancer work-up appears very promising without safety concerns, giving the pulmonologist access to a variety of sites out of reach with other minimally invasive techniques. Little is known on patient-reported outcomes and costs. Future and prospective research should focus on effectiveness aspects to clarify whether overall benefits of add-on EUS-B sufficiently exceed overall downsides.

背景:支气管镜检查和 EBUS 是肺癌检查的标准程序,但对中央气道和腹腔/纵隔淋巴结以外的病变诊断率较低。越来越多的证据表明,在支气管镜/EBUS检查的同时将EBUS内窥镜引入食道(EUS-B),可进入新的解剖区域进行安全活检:目的:总结EUS-B-FNA与支气管镜检查和EBUS-TBNA在肺癌检查中的附加价值的现有证据:方法:叙述性综述:很少有随机试验或前瞻性研究。前瞻性研究显示,在采样异常纵隔淋巴结、食管旁肺和左肾上腺时,附加 EUS-B-FNA 可提高诊断率。一项关于腹膜后淋巴结 EUS-B-FNA 的大型回顾性系列研究表明,诊断率高且无安全问题,关于纵隔胸膜增厚、胰腺病变、腹水和心包积液 EUS-B-FNA 的病例报告也是如此。目前还没有研究对诊断率、安全性、患者报告结果、不良事件和成本进行系统评估:结论:在标准支气管镜检查和 EBUS 检查的基础上增加 EUS-B 对肺癌检查的诊断价值似乎很有希望,而且没有安全问题,可让肺科医生检查其他微创技术无法检查到的各种部位。关于患者报告的结果和成本,目前所知甚少。未来的前瞻性研究应重点关注有效性方面,以明确附加 EUS-B 的总体益处是否足以超过总体弊端。
{"title":"Added value of EUS-B-FNA to bronchoscopy and EBUS-TBNA in diagnosing and staging of lung cancer.","authors":"Mohammad A Issa, Paul F Clementsen, Christian B Laursen, Ida S Christiansen, Laurence Crombag, Peter Vilmann, Uffe Bodtger","doi":"10.1080/20018525.2024.2362995","DOIUrl":"10.1080/20018525.2024.2362995","url":null,"abstract":"<p><strong>Background: </strong>Bronchoscopy and EBUS are standard procedures in lung cancer work-up but have low diagnostic yield in lesions outside the central airways and hilar/mediastinal lymph nodes. Growing evidence on introducing the EBUS endoscope into the oesophagus (EUS-B) in the same session as bronchoscopy/EBUS gives access to new anatomical areas that can be safely biopsied.</p><p><strong>Objective: </strong>To summarize the current evidence of the added value of EUS-B-FNA to bronchoscopy and EBUS-TBNA in lung cancer work-up.</p><p><strong>Methods: </strong>A narrative review.</p><p><strong>Results: </strong>Few randomized trials or prospective studies are available. Prospective studies show that add-on EUS-B-FNA increases diagnostic yield when sampling abnormal mediastinal lymph nodes, para-oesophageal lung and left adrenal gland. A large retrospective series on EUS-B-FNA from retroperitoneal lymph nodes suggests high diagnostic yield without safety concerns, as do casuistic reports on EUS-B-FNA from mediastinal pleural thickening, pancreatic lesions, ascites fluid and pericardial effusions. No study has systematically assessed both diagnostic yield, safety, patient reported outcomes, adverse events and costs.</p><p><strong>Conclusion: </strong>The diagnostic value of add-on EUS-B to standard bronchoscopy and EBUS in lung cancer work-up appears very promising without safety concerns, giving the pulmonologist access to a variety of sites out of reach with other minimally invasive techniques. Little is known on patient-reported outcomes and costs. Future and prospective research should focus on effectiveness aspects to clarify whether overall benefits of add-on EUS-B sufficiently exceed overall downsides.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease - nationwide development from 1998 to 2018. 吸入皮质类固醇治疗与慢性阻塞性肺病患者的肺炎--1998 年至 2018 年的全国发展情况。
IF 1.9 Q3 Medicine Pub Date : 2024-05-29 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2024.2359768
Allan Klitgaard, Rikke Ibsen, Jesper Lykkegaard, Ole Hilberg, Anders Løkke

Background: A decreasing use of inhaled corticosteroids (ICS) in patients with a hospital-registered diagnosis of chronic obstructive pulmonary disease (COPD) has recently been documented in Denmark. ICS treatment is not recommended in patients with high pneumonia risk, and we aimed to assess the development of ICS treatment in relation to pneumonia occurrence.

Methods: Annual nationwide register-based cross-sectional studies from 1998 to 2018 including all patients ≥40 years of age with a hospital-registered ICD-10 diagnosis of COPD on the 31st of December each year. We calculated the annual proportion of patients with at least one outpatient pneumonia (redeemed prescription of relevant antibiotics) or pneumonia hospitalization (hospitalization or ER visit), and stratified by ICS dose (No ICS, low dose, medium dose, or high dose).

Results: The study population increased from 35,656 patients in 1998 to 99,057 patients in 2018. The annual proportion of patients experiencing a pneumonia decreased from 69.4% to 55.2%. The proportion of patients with at least one outpatient pneumonia, but no hospitalization, decreased (59.2% to 46.2%). The overall proportion of patients with at least one pneumonia hospitalization remained unchanged (10.2% to 9.0%), but this proportion increased in patients in high dose ICS (9.9% to 14.6%). The overall proportion of patients in high dose treatment decreased (12.7% to 5.7%), but not in patients with pneumonia hospitalization (16.5% to 15.1).

Conclusions: Our study demonstrates a nationwide decrease from 1998 to 2018 in the proportion of patients who redeemed a prescription for antibiotics used mainly for respiratory tract infections, which may reflect a decrease in the number of outpatient pneumonias. This decrease was largely caused by an increase in the number of patients without pneumonia. No differences over time were seen regarding hospitalization-requiring pneumonia. High dose ICS treatment was unchanged in patients with hospitalization-requiring pneumonia.

背景:最近,在丹麦,经医院登记确诊为慢性阻塞性肺病(COPD)的患者使用吸入性皮质类固醇(ICS)的情况有所减少。我们的目的是评估 ICS 治疗的发展与肺炎发生率的关系:1998年至2018年期间每年在全国范围内进行的基于登记的横断面研究,包括每年12月31日在医院登记的ICD-10诊断为慢性阻塞性肺病的所有年龄≥40岁的患者。我们计算了每年至少有一次肺炎门诊(兑换相关抗生素处方)或肺炎住院(住院或急诊室就诊)的患者比例,并按 ICS 剂量(无 ICS、低剂量、中剂量或高剂量)进行了分层:研究人群从1998年的35656名患者增加到2018年的99057名患者。每年发生肺炎的患者比例从 69.4% 降至 55.2%。至少有一次门诊肺炎但未住院的患者比例有所下降(59.2% 降至 46.2%)。至少有一次肺炎住院治疗的患者总比例保持不变(从 10.2% 降至 9.0%),但大剂量 ICS 患者的这一比例有所上升(从 9.9% 升至 14.6%)。接受大剂量治疗的患者总体比例有所下降(从 12.7% 降至 5.7%),但肺炎住院患者的比例没有下降(从 16.5% 降至 15.1):我们的研究表明,从 1998 年到 2018 年,全国范围内兑换主要用于呼吸道感染的抗生素处方的患者比例有所下降,这可能反映了门诊肺炎数量的减少。这一下降主要是由非肺炎患者人数的增加造成的。在需要住院治疗的肺炎方面,没有发现不同时期的差异。需要住院治疗的肺炎患者接受大剂量 ICS 治疗的情况没有变化。
{"title":"Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease - nationwide development from 1998 to 2018.","authors":"Allan Klitgaard, Rikke Ibsen, Jesper Lykkegaard, Ole Hilberg, Anders Løkke","doi":"10.1080/20018525.2024.2359768","DOIUrl":"10.1080/20018525.2024.2359768","url":null,"abstract":"<p><strong>Background: </strong>A decreasing use of inhaled corticosteroids (ICS) in patients with a hospital-registered diagnosis of chronic obstructive pulmonary disease (COPD) has recently been documented in Denmark. ICS treatment is not recommended in patients with high pneumonia risk, and we aimed to assess the development of ICS treatment in relation to pneumonia occurrence.</p><p><strong>Methods: </strong>Annual nationwide register-based cross-sectional studies from 1998 to 2018 including all patients ≥40 years of age with a hospital-registered ICD-10 diagnosis of COPD on the 31<sup>st</sup> of December each year. We calculated the annual proportion of patients with at least one outpatient pneumonia (redeemed prescription of relevant antibiotics) or pneumonia hospitalization (hospitalization or ER visit), and stratified by ICS dose (No ICS, low dose, medium dose, or high dose).</p><p><strong>Results: </strong>The study population increased from 35,656 patients in 1998 to 99,057 patients in 2018. The annual proportion of patients experiencing a pneumonia decreased from 69.4% to 55.2%. The proportion of patients with at least one outpatient pneumonia, but no hospitalization, decreased (59.2% to 46.2%). The overall proportion of patients with at least one pneumonia hospitalization remained unchanged (10.2% to 9.0%), but this proportion increased in patients in high dose ICS (9.9% to 14.6%). The overall proportion of patients in high dose treatment decreased (12.7% to 5.7%), but not in patients with pneumonia hospitalization (16.5% to 15.1).</p><p><strong>Conclusions: </strong>Our study demonstrates a nationwide decrease from 1998 to 2018 in the proportion of patients who redeemed a prescription for antibiotics used mainly for respiratory tract infections, which may reflect a decrease in the number of outpatient pneumonias. This decrease was largely caused by an increase in the number of patients without pneumonia. No differences over time were seen regarding hospitalization-requiring pneumonia. High dose ICS treatment was unchanged in patients with hospitalization-requiring pneumonia.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11138226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship of gastroesophageal reflux disease and asthma control. 胃食管反流病与哮喘控制的关系。
IF 1.9 Q3 Medicine Pub Date : 2024-05-11 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2024.2348267
Arzoe Singh, Rahul Khanna, Annya Suman, Jack Pollack, Sudhir Sekhsaria

Purpose: To study whether ACT responses are confounded by gastro-esophageal status (GERD), and if this is in concordance with the variation in Forced Expiratory Volume in 1 second (FEV1%) and Fractional Excretion of Nitric Oxide (FeNO).

Materials and methods: This is a prospective cohort study (n = 307). Patients were surveyed for demographics data, and underwent ACT scoring, FEV1% and FeNO testing.

Results: Patients with GERD had mean ACT scores that were 4.1 (p < .001) lower than without-GERD group. Not-well-controlled asthmatics (FEV1% <80, high FeNO) with-GERD had mean ACT scores that were 2.9 (p < .001) for FEV1% <80 and 3.8 (p = .008) for high FeNO lower than without-GERD group respectively. Well-controlled asthmatics (FEV1% ≥80, low FeNO) with-GERD had mean ACT scores that were 5.2 (p < .001) for FEV1% ≥80 and 5.1 (p < .001) for low FeNO lower than without-GERD group respectively.

Conclusion: Our study demonstrates that symptoms of GERD can lead to an inaccurate perception of asthma control and ACT as compared to objective measures, such as FEV1% and FeNO. Hence, this can lead to mismanagement of asthma, especially when objective measures are not conducted along with ACT.

目的:研究 ACT 反应是否受到胃食管反流状态(GERD)的影响,以及这种影响是否与 1 秒内用力呼气容积(FEV1%)和一氧化氮分排泄量(FeNO)的变化一致:这是一项前瞻性队列研究(n = 307)。患者接受了人口统计学数据调查,并接受了 ACT 评分、FEV1% 和 FeNO 测试:结果:胃食管反流病患者的平均 ACT 评分为 4.1 分(p p = .008),而高 FeNO 评分则分别低于无胃食管反流病患者组。胃食管反流患者中,哮喘控制良好者(FEV1% ≥80,低 FeNO)的平均 ACT 得分为 5.2(p p p 结论:我们的研究表明,胃食管反流患者的症状与哮喘控制良好者(FEV1% ≥80,低 FeNO)的症状相似:我们的研究表明,与 FEV1% 和 FeNO 等客观指标相比,胃食管反流病的症状会导致对哮喘控制和 ACT 的认识不准确。因此,这可能会导致哮喘管理不善,尤其是在没有进行客观测量和哮喘治疗的情况下。
{"title":"The relationship of gastroesophageal reflux disease and asthma control.","authors":"Arzoe Singh, Rahul Khanna, Annya Suman, Jack Pollack, Sudhir Sekhsaria","doi":"10.1080/20018525.2024.2348267","DOIUrl":"10.1080/20018525.2024.2348267","url":null,"abstract":"<p><strong>Purpose: </strong>To study whether ACT responses are confounded by gastro-esophageal status (GERD), and if this is in concordance with the variation in Forced Expiratory Volume in 1 second (FEV1%) and Fractional Excretion of Nitric Oxide (FeNO).</p><p><strong>Materials and methods: </strong>This is a prospective cohort study (<i>n</i> = 307). Patients were surveyed for demographics data, and underwent ACT scoring, FEV1% and FeNO testing.</p><p><strong>Results: </strong>Patients with GERD had mean ACT scores that were 4.1 (<i>p</i> < .001) lower than without-GERD group. Not-well-controlled asthmatics (FEV1% <80, high FeNO) with-GERD had mean ACT scores that were 2.9 (<i>p</i> < .001) for FEV1% <80 and 3.8 (<i>p</i> = .008) for high FeNO lower than without-GERD group respectively. Well-controlled asthmatics (FEV1% ≥80, low FeNO) with-GERD had mean ACT scores that were 5.2 (<i>p</i> < .001) for FEV1% ≥80 and 5.1 (<i>p</i> < .001) for low FeNO lower than without-GERD group respectively.</p><p><strong>Conclusion: </strong>Our study demonstrates that symptoms of GERD can lead to an inaccurate perception of asthma control and ACT as compared to objective measures, such as FEV1% and FeNO. Hence, this can lead to mismanagement of asthma, especially when objective measures are not conducted along with ACT.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11089934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Musculoskeletal aspects of respiratory function in cystic fibrosis: a cross-sectional comparative study. 囊性纤维化患者呼吸功能的肌肉骨骼方面:一项横断面比较研究。
IF 1.9 Q3 Medicine Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2024.2350206
Niklas Sinderholm Sposato, Kristofer Bjerså, Marita Gilljam, Louise Lannefors, Monika Fagevik Olsén

Background: Respiration is an intricate interaction between visceral and musculoskeletal structures. In cystic fibrosis (CF), the airways and lungs are subject to progressive obstruction and destruction. However, knowledge about the musculoskeletal aspects of respiratory function and symptoms is still limited in this patient group.

Methods: In a cross-sectional comparative study, 21 adults with CF enrolled at the Gothenburg CF Centre were matched with 42 healthy controls. The two groups were examined and compared in terms of thoracic mobility, respiratory muscle strength, lung function, and musculoskeletal pain in accordance with a predefined protocol.

Results: Significant differences were observed between the groups in the number of tender points, thoracic excursion, forced vital capacity (FVC), and forced expiratory volume (FEV). The CF group also demonstrated a tendency toward reduced function in other measurements, although these were not statistically significant.

Conclusion: This cross-sectional study revealed that people with CF have reduced thoracic mobility and an increased prevalence of muscular tender points, alongside decreased lung function, compared to healthy controls. These findings stress the need for greater emphasis on the often-overlooked musculoskeletal aspects of CF care, especially as people with CF are living longer and may require more musculoskeletal health support.

背景:呼吸是内脏和肌肉骨骼结构之间错综复杂的相互作用。在囊性纤维化(CF)患者中,气道和肺部会受到进行性阻塞和破坏。然而,对于这一患者群体,有关呼吸功能和症状的肌肉骨骼方面的知识仍然有限:在一项横断面比较研究中,哥德堡 CF 中心的 21 名成年 CF 患者与 42 名健康对照者进行了配对。按照预定方案对两组患者的胸廓活动度、呼吸肌力量、肺功能和肌肉骨骼疼痛进行了检查和比较:结果:两组在触痛点数量、胸廓偏移、用力肺活量(FVC)和用力呼气容积(FEV)方面存在显著差异。CF组在其他测量指标上也表现出功能减退的趋势,但在统计学上并不显著:这项横断面研究显示,与健康对照组相比,CF 患者的胸廓活动度降低,肌肉触痛点增加,同时肺功能下降。这些发现强调,有必要更加重视CF护理中经常被忽视的肌肉骨骼方面,尤其是CF患者的寿命越来越长,可能需要更多的肌肉骨骼健康支持。
{"title":"Musculoskeletal aspects of respiratory function in cystic fibrosis: a cross-sectional comparative study.","authors":"Niklas Sinderholm Sposato, Kristofer Bjerså, Marita Gilljam, Louise Lannefors, Monika Fagevik Olsén","doi":"10.1080/20018525.2024.2350206","DOIUrl":"10.1080/20018525.2024.2350206","url":null,"abstract":"<p><strong>Background: </strong>Respiration is an intricate interaction between visceral and musculoskeletal structures. In cystic fibrosis (CF), the airways and lungs are subject to progressive obstruction and destruction. However, knowledge about the musculoskeletal aspects of respiratory function and symptoms is still limited in this patient group.</p><p><strong>Methods: </strong>In a cross-sectional comparative study, 21 adults with CF enrolled at the Gothenburg CF Centre were matched with 42 healthy controls. The two groups were examined and compared in terms of thoracic mobility, respiratory muscle strength, lung function, and musculoskeletal pain in accordance with a predefined protocol.</p><p><strong>Results: </strong>Significant differences were observed between the groups in the number of tender points, thoracic excursion, forced vital capacity (FVC), and forced expiratory volume (FEV). The CF group also demonstrated a tendency toward reduced function in other measurements, although these were not statistically significant.</p><p><strong>Conclusion: </strong>This cross-sectional study revealed that people with CF have reduced thoracic mobility and an increased prevalence of muscular tender points, alongside decreased lung function, compared to healthy controls. These findings stress the need for greater emphasis on the often-overlooked musculoskeletal aspects of CF care, especially as people with CF are living longer and may require more musculoskeletal health support.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound in predicting improvement in dyspnoea after therapeutic thoracentesis in patients with recurrent unilateral pleural effusion. 超声波预测复发性单侧胸腔积液患者治疗性胸腔穿刺术后呼吸困难的改善情况。
IF 1.9 Q3 Medicine Pub Date : 2024-05-05 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2024.2337446
Katrine Fjaellegaard, Jesper Koefod Petersen, Gitte Alstrup, Søren Skaarup, Paul Frost Clementsen, Christian B Laursen, Rahul Bhatnagar, Uffe Bodtger

Background: In patients with recurrent pleural effusion, therapeutic thoracentesis is one way of relief. Correct prediction of which patients will experience relief following drainage may support the management of these patients. This study aimed to assess the association between ultrasound (US) characteristics and a relevant improvement in dyspnoea immediately following drainage.

Methods: In a prospective, observational study, patients with recurrent unilateral pleural effusion underwent US evaluation of effusion characteristics and diaphragm movement measured by M-mode and the Area method before and right after drainage. The level of dyspnoea was assessed using the modified Borg scale (MBS). A minimal important improvement in dyspnoea was defined as delta MBS ≥ 1.

Results: In the 104 patients included, 53% had a minimal important improvement in dyspnoea following thoracentesis. We found no association between US-characteristics, including diaphragm shape or movement (M-mode or the Area method), and a decrease in dyspnoea following drainage. Baseline MBS score ≥ 4 and a fully drained effusion were significant correlated with a minimal important improvement in dyspnoea (OR 3.86 (1.42-10.50), p = 0.01 and 2.86 (1.03-7.93), p = 0.04, respectively).

Conclusions: In our study population, US-characteristics including assessment of diaphragm movement or shape was not associated with a minimal important improvement in dyspnoea immediately following thoracentesis.

背景:对于复发性胸腔积液患者,治疗性胸腔穿刺术是一种缓解方法。正确预测哪些患者在引流后症状会得到缓解,有助于这些患者的治疗。本研究旨在评估超声(US)特征与引流后呼吸困难立即得到改善之间的关联:在一项前瞻性观察研究中,复发性单侧胸腔积液患者在引流前和引流后立即接受了超声评估,通过 M 型和面积法测量了积液特征和横膈膜运动。呼吸困难程度采用改良博格量表(MBS)进行评估。结果:在纳入的 104 名患者中,53% 的患者在胸腔穿刺术后呼吸困难得到了最小程度的改善。我们发现 US 特征(包括横膈膜形状或移动(M 模式或区域法))与引流后呼吸困难的减轻之间没有关联。基线 MBS 评分≥4 和完全引流的积液与呼吸困难的最小重要改善显著相关(OR 分别为 3.86 (1.42-10.50),p = 0.01 和 2.86 (1.03-7.93),p = 0.04):在我们的研究人群中,包括评估横膈膜运动或形状在内的 US 特征与胸腔穿刺术后呼吸困难的最小重要改善无关。
{"title":"Ultrasound in predicting improvement in dyspnoea after therapeutic thoracentesis in patients with recurrent unilateral pleural effusion.","authors":"Katrine Fjaellegaard, Jesper Koefod Petersen, Gitte Alstrup, Søren Skaarup, Paul Frost Clementsen, Christian B Laursen, Rahul Bhatnagar, Uffe Bodtger","doi":"10.1080/20018525.2024.2337446","DOIUrl":"10.1080/20018525.2024.2337446","url":null,"abstract":"<p><strong>Background: </strong>In patients with recurrent pleural effusion, therapeutic thoracentesis is one way of relief. Correct prediction of which patients will experience relief following drainage may support the management of these patients. This study aimed to assess the association between ultrasound (US) characteristics and a relevant improvement in dyspnoea immediately following drainage.</p><p><strong>Methods: </strong>In a prospective, observational study, patients with recurrent unilateral pleural effusion underwent US evaluation of effusion characteristics and diaphragm movement measured by M-mode and the Area method before and right after drainage. The level of dyspnoea was assessed using the modified Borg scale (MBS). A minimal important improvement in dyspnoea was defined as delta MBS ≥ 1.</p><p><strong>Results: </strong>In the 104 patients included, 53% had a minimal important improvement in dyspnoea following thoracentesis. We found no association between US-characteristics, including diaphragm shape or movement (M-mode or the Area method), and a decrease in dyspnoea following drainage. Baseline MBS score ≥ 4 and a fully drained effusion were significant correlated with a minimal important improvement in dyspnoea (OR 3.86 (1.42-10.50), <i>p</i> = 0.01 and 2.86 (1.03-7.93), <i>p</i> = 0.04, respectively).</p><p><strong>Conclusions: </strong>In our study population, US-characteristics including assessment of diaphragm movement or shape was not associated with a minimal important improvement in dyspnoea immediately following thoracentesis.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adult-onset asthma, allergy, and aspirin hypersensitivity associate with self-reported food avoidance. 成人哮喘、过敏和阿司匹林过敏与自我报告的食物回避有关。
IF 1.9 Q3 Medicine Pub Date : 2024-05-02 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2024.2347073
Marie Lundberg, Helena Voutilainen, Annina Lyly, Jussi Karjalainen, Heini Huhtala, Tanya M Laidlaw, Stella E Lee, Mikko Nuutinen, Sanna Toppila-Salmi

Background: The adoption of avoidance diets by adult-onset asthmatics has not previously been studied. We hypothesized that avoidance diets would associate with adult-onset asthma, allergy, and aspirin-exacerbated respiratory disease (AERD).

Methods: A total of 1247 subjects with adult-onset asthma (age range: 31-91) from the Finnish national registry, and age- and sex-matched controls (n = 1970) participated in a questionnaire study in 1997. We estimated the association between asthma/allergy/AERD and avoidance diets, adjusting for potential confounding factors and validated the results in two retrospective cohorts of 5080 rhinitis/rhinosinusitis patients and 167 AERD patients from 2019 to 2020.

Results: The presence of asthma positively associated with adoption of any avoidance diet (adjusted OR [CI95%] 1.24 [1.02-1.51], p = 0.029) as did allergic disease and self-reported AERD within the asthmatic group (1.79 [1.29-2.48], p = 0.001 and 1.69 [1.15-2.49], p = 0.007, respectively). Asthmatics and allergic asthmatics were more likely to report avoidance of fish, fruits and vegetables, and spices (p ≤ 0.03) compared to controls and non-allergic asthmatics. The adjusted OR for multiple diets among AERD patients was 2.57 [1.34-4.95] p = 0.005. In the validation, 26.2% of the allergic asthmatics and 10.8% of AERD patients had documented avoidance diets.

Conclusions: Our study shows a positive association between avoidance diets and adult-onset asthma, and with allergic disease or AERD within asthmatic patients. Although we lack information on the reason patients chose to observe a specific diet, our results reinforce the importance of asking patients about their diet and if needed, giving dietary advice for adult asthma patients to help them avoid the adoption of unnecessarily restrictive diets.

背景:以前从未研究过成年哮喘患者采用忌口饮食的情况。我们假设忌口饮食与成人哮喘、过敏和阿司匹林加重呼吸道疾病(AERD)有关:1997年,来自芬兰国家登记处的1247名成人哮喘患者(年龄在31-91岁之间)以及年龄和性别匹配的对照组(n = 1970)参加了一项问卷调查。我们估算了哮喘/过敏/肺气肿与忌口饮食之间的关系,调整了潜在的混杂因素,并在2019年至2020年的两个回顾性队列中对5080名鼻炎/鼻窦炎患者和167名肺气肿患者的结果进行了验证:哮喘与采用任何忌口饮食呈正相关(调整后 OR [CI95%]为 1.24 [1.02-1.51],p = 0.029),哮喘组中的过敏性疾病和自我报告的 AERD 也是如此(分别为 1.79 [1.29-2.48],p = 0.001 和 1.69 [1.15-2.49],p = 0.007)。与对照组和非过敏性哮喘患者相比,哮喘患者和过敏性哮喘患者更有可能报告避免食用鱼类、水果和蔬菜以及香料(p ≤ 0.03)。过敏性哮喘患者多种饮食的调整 OR 值为 2.57 [1.34-4.95] p = 0.005。在验证中,26.2% 的过敏性哮喘患者和 10.8% 的过敏性胃食管反流病患者有忌口的记录:我们的研究表明,忌口与成人哮喘、过敏性疾病或哮喘性呼吸道疾病之间存在正相关。虽然我们缺乏有关患者选择特定饮食的原因的信息,但我们的研究结果加强了询问患者饮食情况的重要性,并在必要时为成年哮喘患者提供饮食建议,以帮助他们避免采用不必要的限制性饮食。
{"title":"Adult-onset asthma, allergy, and aspirin hypersensitivity associate with self-reported food avoidance.","authors":"Marie Lundberg, Helena Voutilainen, Annina Lyly, Jussi Karjalainen, Heini Huhtala, Tanya M Laidlaw, Stella E Lee, Mikko Nuutinen, Sanna Toppila-Salmi","doi":"10.1080/20018525.2024.2347073","DOIUrl":"https://doi.org/10.1080/20018525.2024.2347073","url":null,"abstract":"<p><strong>Background: </strong>The adoption of avoidance diets by adult-onset asthmatics has not previously been studied. We hypothesized that avoidance diets would associate with adult-onset asthma, allergy, and aspirin-exacerbated respiratory disease (AERD).</p><p><strong>Methods: </strong>A total of 1247 subjects with adult-onset asthma (age range: 31-91) from the Finnish national registry, and age- and sex-matched controls (<i>n</i> = 1970) participated in a questionnaire study in 1997. We estimated the association between asthma/allergy/AERD and avoidance diets, adjusting for potential confounding factors and validated the results in two retrospective cohorts of 5080 rhinitis/rhinosinusitis patients and 167 AERD patients from 2019 to 2020.</p><p><strong>Results: </strong>The presence of asthma positively associated with adoption of any avoidance diet (adjusted OR [CI95%] 1.24 [1.02-1.51], <i>p</i> = 0.029) as did allergic disease and self-reported AERD within the asthmatic group (1.79 [1.29-2.48], <i>p</i> = 0.001 and 1.69 [1.15-2.49], <i>p</i> = 0.007, respectively). Asthmatics and allergic asthmatics were more likely to report avoidance of fish, fruits and vegetables, and spices (<i>p</i> ≤ 0.03) compared to controls and non-allergic asthmatics. The adjusted OR for multiple diets among AERD patients was 2.57 [1.34-4.95] <i>p</i> = 0.005. In the validation, 26.2% of the allergic asthmatics and 10.8% of AERD patients had documented avoidance diets.</p><p><strong>Conclusions: </strong>Our study shows a positive association between avoidance diets and adult-onset asthma, and with allergic disease or AERD within asthmatic patients. Although we lack information on the reason patients chose to observe a specific diet, our results reinforce the importance of asking patients about their diet and if needed, giving dietary advice for adult asthma patients to help them avoid the adoption of unnecessarily restrictive diets.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11067555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of predictors for in-hospital death or long-term hospitalization in community-acquired pneumonia with risk factors for aspiration 对有吸入风险因素的社区获得性肺炎患者院内死亡或长期住院预测因素的调查
IF 1.9 Q3 Medicine Pub Date : 2024-04-04 DOI: 10.1080/20018525.2024.2335721
Issei Oi, Isao Ito, N. Tanabe, Satoshi Konishi, Yumiko Ibi, Yu Hidaka, Nobuyoshi Hamao, Masahiro Shirata, Kensuke Nishioka, S. Imai, Yoshiro Yasutomo, S. Kadowaki, T. Hirai
ABSTRACT Background It is known that the mortality of pneumonia in patients with risk factors for aspiration is worse than that in those without these risk factors. However, it is still unknown which risk factors for aspiration predict prognosis. Therefore, we aimed to determine which risk factors for aspiration are associated with death or prolonged hospitalization. Methods We prospectively followed patients with community-acquired pneumonia at a single hospital providing acute to chronic care in Japan until they died or were discharged. Patients at any risk of aspiration were included. The associations between pneumonia severity, individual risk factors for aspiration, and in-hospital death or prolonged hospitalization were investigated. Overall survival was estimated by the Kaplan – Meier method, and the factors associated with in-hospital death or prolonged hospitalization were investigated by multivariate analysis using factors selected by a stepwise method. Results In total, 765 patients with pneumonia and risk factors for aspiration were recruited. One hundred and ten patients deceased, and 259 patients were hospitalized over 27 days. In-hospital death increased as the number of risk factors for aspiration increased. In the multivariate analysis, male, impaired consciousness, acidemia, elevated blood urea nitrogen, and bedridden status before the onset of pneumonia were associated with in-hospital death (odds ratio [OR]: 2.5, 2.5, 3.6, 3.1, and 2.6; 95% confidence interval [CI]: 1.6–4.1, 1.4–4.2, 1.6–8.0, 1.9–5.0, and 1.6–4.2 respectively). In the Cox regression analysis, these factors were also associated with in-hospital death. None of the vital signs at admission were associated. Tachycardia, elevated blood urea nitrogen, hyponatremia, and bedridden status were associated with hospitalization for >27 days (OR: 4.1, 2.3, 4.3, and 2.9; 95% CI: 1.3–12.9, 1.5–3.4, 2.0–9.4, and 2.0–4.0, respectively). Conclusions Blood sampling findings and bedridden status are useful for predicting in-hospital mortality and long-term hospitalization in patients with pneumonia and any risk factor for aspiration.
摘要 背景 众所周知,有误吸风险因素的肺炎患者的死亡率要比没有这些风险因素的患者低。然而,哪些吸入风险因素可预测预后仍是未知数。因此,我们旨在确定哪些吸入风险因素与死亡或住院时间延长相关。方法 我们在日本一家提供急慢性治疗的医院对社区获得性肺炎患者进行了前瞻性随访,直至患者死亡或出院。有吸入风险的患者均被纳入研究范围。我们研究了肺炎严重程度、吸入风险因素、院内死亡或住院时间延长之间的关系。采用卡普兰-迈尔法估算总生存率,并采用逐步法筛选出的因素进行多变量分析,研究与院内死亡或住院时间延长相关的因素。结果 共招募了 765 名具有吸入风险因素的肺炎患者。110名患者死亡,259名患者住院超过27天。随着吸入风险因素的增加,住院死亡人数也随之增加。在多变量分析中,男性、意识障碍、酸血症、血尿素氮升高和肺炎发病前卧床状态与院内死亡有关(几率比 [OR]:2.5、2.5、3.6、3.1 和 2.6;95% 置信区间 [CI]:分别为 1.6-4.1、1.4-4.2、1.6-8.0、1.9-5.0 和 1.6-4.2)。在 Cox 回归分析中,这些因素也与院内死亡有关。入院时的生命体征均与死亡无关。心动过速、血尿素氮升高、低钠血症和卧床状态与住院时间超过 27 天有关(OR:分别为 4.1、2.3、4.3 和 2.9;95% CI:分别为 1.3-12.9、1.5-3.4、2.0-9.4 和 2.0-4.0)。结论 血液采样结果和卧床状态有助于预测肺炎患者的院内死亡率和长期住院率,并可用于任何吸入风险因素。
{"title":"Investigation of predictors for in-hospital death or long-term hospitalization in community-acquired pneumonia with risk factors for aspiration","authors":"Issei Oi, Isao Ito, N. Tanabe, Satoshi Konishi, Yumiko Ibi, Yu Hidaka, Nobuyoshi Hamao, Masahiro Shirata, Kensuke Nishioka, S. Imai, Yoshiro Yasutomo, S. Kadowaki, T. Hirai","doi":"10.1080/20018525.2024.2335721","DOIUrl":"https://doi.org/10.1080/20018525.2024.2335721","url":null,"abstract":"ABSTRACT Background It is known that the mortality of pneumonia in patients with risk factors for aspiration is worse than that in those without these risk factors. However, it is still unknown which risk factors for aspiration predict prognosis. Therefore, we aimed to determine which risk factors for aspiration are associated with death or prolonged hospitalization. Methods We prospectively followed patients with community-acquired pneumonia at a single hospital providing acute to chronic care in Japan until they died or were discharged. Patients at any risk of aspiration were included. The associations between pneumonia severity, individual risk factors for aspiration, and in-hospital death or prolonged hospitalization were investigated. Overall survival was estimated by the Kaplan – Meier method, and the factors associated with in-hospital death or prolonged hospitalization were investigated by multivariate analysis using factors selected by a stepwise method. Results In total, 765 patients with pneumonia and risk factors for aspiration were recruited. One hundred and ten patients deceased, and 259 patients were hospitalized over 27 days. In-hospital death increased as the number of risk factors for aspiration increased. In the multivariate analysis, male, impaired consciousness, acidemia, elevated blood urea nitrogen, and bedridden status before the onset of pneumonia were associated with in-hospital death (odds ratio [OR]: 2.5, 2.5, 3.6, 3.1, and 2.6; 95% confidence interval [CI]: 1.6–4.1, 1.4–4.2, 1.6–8.0, 1.9–5.0, and 1.6–4.2 respectively). In the Cox regression analysis, these factors were also associated with in-hospital death. None of the vital signs at admission were associated. Tachycardia, elevated blood urea nitrogen, hyponatremia, and bedridden status were associated with hospitalization for >27 days (OR: 4.1, 2.3, 4.3, and 2.9; 95% CI: 1.3–12.9, 1.5–3.4, 2.0–9.4, and 2.0–4.0, respectively). Conclusions Blood sampling findings and bedridden status are useful for predicting in-hospital mortality and long-term hospitalization in patients with pneumonia and any risk factor for aspiration.","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140744768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of bronchodilator responsiveness to salbutamol or ipratropium using different criteria in treatment-naïve patients with asthma and COPD 采用不同标准评估哮喘和慢性阻塞性肺病新患者对舒喘宁或异丙托品的支气管扩张剂反应性
IF 1.9 Q3 Medicine Pub Date : 2024-03-21 DOI: 10.1080/20018525.2024.2328434
Z. Lázár, A. Horváth, Szilvia Kiss-Dala, Z. Abonyi-Tóth, Balázs Csoma, Katalin Kontz, L. Tamási, Veronika Müller
{"title":"Assessment of bronchodilator responsiveness to salbutamol or ipratropium using different criteria in treatment-naïve patients with asthma and COPD","authors":"Z. Lázár, A. Horváth, Szilvia Kiss-Dala, Z. Abonyi-Tóth, Balázs Csoma, Katalin Kontz, L. Tamási, Veronika Müller","doi":"10.1080/20018525.2024.2328434","DOIUrl":"https://doi.org/10.1080/20018525.2024.2328434","url":null,"abstract":"","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140224388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood group O is associated with ARDS development but exhibits lower mortality in the intensive care unit – A retrospective multicentre study O 型血与急性呼吸缺氧症的发生有关,但在重症监护室中的死亡率较低 - 一项回顾性多中心研究
IF 1.9 Q3 Medicine Pub Date : 2024-03-14 DOI: 10.1080/20018525.2024.2327177
Hazem Koozi, Alma Dannäs, Patrik Johnsson, A. Frigyesi
{"title":"Blood group O is associated with ARDS development but exhibits lower mortality in the intensive care unit – A retrospective multicentre study","authors":"Hazem Koozi, Alma Dannäs, Patrik Johnsson, A. Frigyesi","doi":"10.1080/20018525.2024.2327177","DOIUrl":"https://doi.org/10.1080/20018525.2024.2327177","url":null,"abstract":"","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140243428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case series of complicated bronchopulmonary lophomoniasis. Differential diagnosis of tuberculosis? 复杂性支气管肺吸虫病病例系列。肺结核的鉴别诊断?
IF 1.9 Q3 Medicine Pub Date : 2024-03-06 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2024.2325170
Cristian Morán-Mariños, Juan Salas López, Felix Llanos-Tejada, Renato Casanova-Mendoza, Renzo Villanueva-Villegas, Antonella Chavez-Huamani, Kenneth G Vargas-Ponce, Margaret Condori-Zevallos

Pulmonary lophomoniasis is a rare and life-threatening disease, most commonly reported across Asian and Latin American countries. Here, we have reported two cases of pulmonary lophomoniasis presenting with atypical manifestations. Case #1 represents a 19-year-old male patient with clinical characteristics suggestive of tuberculosis, presenting with hemoptysis and receiving antituberculosis treatment. Case #2 represents a 69-year-old man with post-tuberculosis pulmonary disease with cystic bronchiectasis presenting with polymicrobial co-infection. Based on our case experience, lophomoniasis should be considered in patients with pneumonia who do not respond to antibiotic treatment, and the corresponding epidemiological factors should be carefully considered in addition to bronchoscopy for precise diagnosis.

肺吸虫病是一种罕见的危及生命的疾病,在亚洲和拉丁美洲国家最常见。在此,我们报告了两例表现不典型的肺吸虫病病例。病例 1 是一名 19 岁的男性患者,临床特征提示为肺结核,出现咯血并正在接受抗结核治疗。病例 2 代表一名 69 岁的男性患者,患有结核病后肺部疾病,伴有囊性支气管扩张,并出现多微生物合并感染。根据我们的病例经验,对抗生素治疗无效的肺炎患者应考虑嗜血杆菌病,除支气管镜检查外,还应仔细考虑相应的流行病学因素,以进行精确诊断。
{"title":"Case series of complicated bronchopulmonary lophomoniasis. Differential diagnosis of tuberculosis?","authors":"Cristian Morán-Mariños, Juan Salas López, Felix Llanos-Tejada, Renato Casanova-Mendoza, Renzo Villanueva-Villegas, Antonella Chavez-Huamani, Kenneth G Vargas-Ponce, Margaret Condori-Zevallos","doi":"10.1080/20018525.2024.2325170","DOIUrl":"10.1080/20018525.2024.2325170","url":null,"abstract":"<p><p>Pulmonary lophomoniasis is a rare and life-threatening disease, most commonly reported across Asian and Latin American countries. Here, we have reported two cases of pulmonary lophomoniasis presenting with atypical manifestations. Case #1 represents a 19-year-old male patient with clinical characteristics suggestive of tuberculosis, presenting with hemoptysis and receiving antituberculosis treatment. Case #2 represents a 69-year-old man with post-tuberculosis pulmonary disease with cystic bronchiectasis presenting with polymicrobial co-infection. Based on our case experience, lophomoniasis should be considered in patients with pneumonia who do not respond to antibiotic treatment, and the corresponding epidemiological factors should be carefully considered in addition to bronchoscopy for precise diagnosis.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140058978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Clinical Respiratory Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1